术前血小板计数和肿瘤最大径比对非转移性胃癌患者的预后作用

Prognostic role of pre-operative platelet count and maximum tumor size ratio for non-metastatic gastric cancer patients

目的探讨术前血小板计数和肿瘤最大径比(platelet count and maximum tumor size ratio, PTR)对非转移性胃癌患者患者3年无疾病生存期(disease free survival,DFS)的预测价值。方法收集我院自2012年12月-2018年6月经根治术后病理确诊的非转移性胃腺癌患者75例,收集患者术前血小板计数和性别、年龄等临床参数,结合肿瘤大小进一步统计分析。结果 PTR对判断患者3年DFS存在一定价值(AUC=0.35,95%CI=0.21-0.48,p=0.027),当其取值为67.58时,其预测3年DFS的敏感性为70.20%,特异性为64.30%;以67.58为界,PTR高于界值的患者预后较好(Log Rank=8.98, p=0.003),总生存时间明显长于低于界值的患者(35.63±17.61月vs 23.49±17.54月,Z=-2.80,p=0.005)。结论 PTR对非转移性胃癌患者3年DFS预测存在一定价值,其中PTR较高的患者预后相对较好。

Objective To explore the prognostic role of pre-operative platelet count and maximum tumor size ratio(PTR) in predicting the 3-year disease free survival(DFS) for gastric cancer patients.Methods Seventy-five patients who were pathological confirmed as adenocarcinoma underwent radical gastrectomy were collected from December 2012 to June 2018 in our hospital, pre-operative platelet count and other parameters including patients’ gender, age were registered and further statistical analysis were conducted along with the tumor size. Results 1. PTR could have a predicting value for the patients(AUC=0.35, 95%CI=0.21-0.48, p=0.027), when the cut-off value set at 67.58, it has a sensitivity and specificity at 70.20%and 64.30% respectively;2. Patients with higher PTR had a superior prognosis compared with the counterparts(Log Rank=8.98, p=0.003), their DFS was extended(35.63 ±17.61 m vs 23.49 ±17.54 m, Z=-2.80,p =0.005). Conclusion PTR could have some prognostic value for non-metastatic gastric cancer patients,an elevation of it can associated with better DFS.